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Abstract
Background: The treatment of chronic nonbacterial prostatitis remains an unexplained urology problem. Adenoprosin is a new entomological product 
containing lipoprotein extract of Lepidopteran insect species. Laboratory studies of the product have shown that it possesses antioxidant, antiproliferative 
and anti-inflammatory properties. 
Material and methods: Nonbacterial prostatitis was experimentally modeled on 100 white Wistar rats. Adenoprosin, 150 mg rectal suppositories, was 
tested against the reference product Vitaprost, 50 mg rectal suppositories and placebo on both the aseptic acute and chronic non-bacterial prostatitis 
models. In the acute prostatitis model, treatment lasted 7 days and in chronic prostatitis 15 days. The treatment efficacy criteria consisted of assessment 
of the general condition and histological results.
Results: In rats receiving Adenoprosin, the microscopic image of the prostate showed a decrease in the severity of the inflammatory process, in both 
acute aseptic and chronic nonbacterial prostatitis, manifested by the recovery on the surface of the epithelial cells in the stromal area of the prostate, and 
decrease in vascular congestion and number of acini with desquamated epithelium.
Conclusions: The product of entomological origin Adenoprosin, showed an obvious anti-inflammatory effect in the experimental model of aseptic acute 
or chronic non-bacterial prostatitis induced on Wistar white rats, similar to the Vitaprost reference product, and significant compared to placebo (p<0.05).
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Introduction
Prostate diseases have been and continue to remain a 
major and controversial issue in urology. Prostatitis is the 
acute or chronic inflammation of the prostate gland and is 
characterized by the presence of pain in the groin, pelvic area 
or genitals, frequent urination, dysuria (difficulty urinating or 
burning sensation when urinating), and in acute inflammation 
flu-like symptoms. The persistence of prostate symptomato-
logy has a negative impact on patient’s sexual life and quality 
of life [1, 2, 3, 4].
The controversy begins with prevalence studies and ends 
with treatment methods. The prevalence of chronic prostati-
tis in the general population fluctuates from 10 to 38%, and 
that assessed by using validated NIH-CPSI questionnaires 
proposed by USA National Institute of Public Health, from 
10 to 14% [5, 6, 7].
Though thousands of articles have been published, some 
clinicians tend to underestimate the illness and its conse-
quences, and others to overdiagnose, especially attributing 
sexual complaints. Other controversies also arise in termi-
nology; the term prostatitis involves the presence of an in-
flammatory disease, whereas bacterial infection itself is pres-
ent in prostatitis patients in only 10% of cases. Approximately 
40-60% of patients will have leukocytes and no bacteria, and 
the remaining 30-40% will have chronic aseptic prostatitis, 
prostatodynia, or chronic painful pelvic syndrome.
Without a clear classification of chronic prostatitis, treat-
ment methods remain controversial and often uncertain. 
The role of antibacterial therapy is well defined for acute or 
chronic bacterial prostatitis, and uncertain for aseptic pros-
tatitis and chronic pelvic pain syndrome [8, 9, 10].
For a deeper study of the causes of nonbacterial prosta-
titis, and their testing various treatment methods have been 
proposed among them several experimental models of pros-
tatitis, that mimic human chronic prostatitis phenotype. 
The closest model is the one induced on white rats. Aseptic 
prostatitis can be induced by several methods, such as direct 
injection into the rat prostate of several substances such as 
ethanol, nitrobenzenesulfonic acid (DNBS), rectal adminis-
tration of turpentine oil, or surgical modeling by zonal sup-
pression of blood circulation. The interval of 12-48 hours 
is sufficient to cause an acute inflammation, and the 30-45 
days period is sufficient for developing aseptic inflammation 
similar to that produced by non-bacterial prostatitis [11, 12, 
13, 14, 15].
Adenoprosin is a product of entomological origin, ob-
tained by using advanced biotechnologies, which contains 
lipoprotein extract from Lepidopteran insect species. The 
product was developed and registered in 2001 within the 
scientific center “New Tone Laboratories” Romania. After 
the preclinical studies at the “Nicolae Testemitsanu” State 
University of Medicine and Pharmacy in the Republic of 
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Moldova and then in Biotehnos Bioanalysis Laboratory, 
Romania, it was demonstrated that Adenoprosin possesses 
antioxidant, antiproliferative, anti-inflammatory and immu-
nomodulating properties.
The purpose of this study is to investigate the anti-in-
flammatory and adverse effects of Adenoprosin, 150 mg rec-
tal suppositories, in experimentally-modeled aseptic prosta-
titis on white Wistar rats.
Material and methods
The study included 120 white Wistar male rats with an 
initial weight of 200 ± 2.1 grams.The acclimation period of 
rats to baseline was 14 days. Animals were randomized into 
6 groups of 10 samples each. Each specimen was marked 
for identification with a specific colorant (eosin or methy-
lene blue) according to laboratory standards. Animal main-
tenance and care were held according to the standards de-
scribed in the “Guide for care and use of Laboratory Animals 
(2011, National Academy Press)” and the ISO P-53434-2009 
standards of Russian Federation [16, 17].
Adenoprosin, 150 mg rectal suppositories, was adminis-
tered rectally as smaller, dose-proportional parts. The dose of 
the product Adenoprosin was calculated as the correspond-
ing dose recommended for human use. Thus 150mg/70kg/24 
hours is equivalent to 2.1mg/kg body weight. The respective 
dose was adjusted for rats using the equivalence coefficient 
of 39/6.5, corresponding to 12.6 mg/kg [18].
The study was performed by comparing with a reference 
product- Vitaprost, 50 mg rectal suppositories, used for a 
long time for the treatment of inflammatory diseases of the 
prostate. The dose of the comparison product, Vitaprost, was 
4.2 mg/kg.
The modelling of acute aseptic inflammation of prostate 
was performed in 50 rats by intra-operative ligation of the 
anterior lobe artery of the prostate with silk ligature. 10 rats 
were not subjected to surgery and were cataloged in the con-
trol group No. 1 – intact.
Four groups of 10 rats each, received Adenorposin med-
ication for 7 days, in two different doses, or the Vitaprost 
comparison medication in two doses. The second dose of 
both products was about 3 times higher the recommended 
dose, i.e. 37.8 mg/kg for Adenoprosin and 12.6 mg/kg for 
Vitaprost.
The second control group consisted of 10 rats with acute 
aseptic prostatitis following placebo treatment (tab. 1).
The efficacy criteria of the treatment consisted of the: as-
sessment of the general condition and the histological results 
performed 7 days after prostate ligation. Morphologically, 
animal necropsy was performed by determining the mac-
roscopic appearance of the prostate, determining prostate 
weight, calculating mass coefficients, and performing micro-
scopic examinations of the area of caused aseptic inflamma-
tion. Anti-inflammatory action was determined by studying 
the quantitative indices of acute inflammation: the surface 
of the epithelial cells in the stromal part of the prostate, the 
surface and level of blood vascularization, the number of 
acini with desquamated epithelium placed on 100 consecu-
tive marginal sections [18].
Table 1
The distribution of white Wistar rats (no. 60)  
with acute aseptic prostatitis under study according to 
study groups treatment
Group 
No
Administered treatment 
No of 
rats
1 Healthy rats/intact rats 10
2 Aseptic Prostatitis. Placebo 10
3 Adenoprosin – recomnended dose (12,6 mg/kg) 10
4 Adenoprosin – recommended x 3 (37,8 mg/kg) 10
5 Vitaprost – recommended dose (4,2 mg/kg) 10
6 Vitaprost – recommended dose x 3 (12,6 mg/kg) 10
The modelling of chronic aseptic prostatitis was achieved 
by intra-operative ligation of the right lobe of prostate gland 
under general anesthesia. The studied product was adminis-
tered 30 days after the surgery for a period of 15 days. The 
distribution of the rat groups according to the administered 
treatment is shown in table 2.
Table 2 
The distribution of white Wistar rats (no. 60) with acute 
aseptic prostatitis according to study groups treatment
Group 
No. Administered Treatment
No 
of 
rats
1 Healthyrats/intactrats 10
2 AsepticProstatitis. Placebo 10
3 Adenoprosin – recomnended dose (12,6 mg/kg) 10
4 Adenoprosin – recommended dose x 3 (37,8 mg/kg) 10
5 Vitaprost – recommended dose (4,2 mg/kg) 10
6 Vitaprost – recommended dose x 3 (12,6 mg/kg) 10
The treatment efficacy criteria were similar to those 
for the study of acute inflammation, with the exception 
that morphological examinations were performed after 
15 days of treatment, respectively 45 days after ligation 
of the right prostate lobe. Anti-inflammatory action was 
determined by studying the quantitative indications of 
chronic inflammation: the surface of the epithelial cells in 
the stromal area of the prostate, the surface and level of 
blood vascularization, the surface of the marginal sections 
of the prostate and the surface of the collagen cells in the 
prostate fibrous tissue layers.
The statistical processing of the data was accomplished 
through the statistical elaboration programs Statistica 5.5. As 
parametric criteria were used Student criteria and non-para-
metric criteria were determined according to the Wilkinson 
or Mann-Whitney criteria. The differences were considered 
true at the veracity level (p <0.05).
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Results
The action of the product Adenoprosin, 150 mg rectal 
suppositories, or Vitaprost, 50 mg rectal suppositories  
on the model of acute prostatitis
The anti-inflammatory action of the studied products 
on the model of acute prostatitis was appreciated. The first 
parameter studied was the general condition of the animals 
and the determination of the body mass (tab. 3). 
Table 3
The dynamic of the body mas index in healthy rats 
and rats with aseptic acute prostatitis under the action of 
administered products
Assessed 
period 
Group 1
healthy
Group 2
Placebo
Adenoprosin® Vitaprost®
T Dose
T x 3 
Dose
T Dose
T x 3 
Dose
Before 
inflam-
mation
299,00 
±1,54
298,90 
±1,73
299,60 
±2,17 
299,20 
±2,41 
301,60 
±2,22 
302,00 
±2,47 
After 7 
days
316,60 
±0,78 
273,90 
±1,55* 
278,60 
±1,20* 
279,50 
±1,93* 
280,60 
±1,77* 
277,50 
±2,25* 
*- statistically veridical difference compared to group 1 (healthy, intact 
rats), p <0.05.
From the table 3, it is clear that the acute aseptic inflam-
mation of the prostate has had a negative impact on the rats’ 
body mass increase in control, placebo group and the groups 
that were treated with Adenoprosin, rectal suppositories, or 
Vitaprost, rectal suppositories.
Pathomorphological studies performed 7 days after the 
onset of acute aseptic prostatitis determined the change in 
prostate weight coefficients, which are statistically veridical 
different (p <0.05) (tab. 4). There is, however, evidence of 
maintenance of the prostate weight coefficient in rats given 
both Adenoprosin and Vitaprost compared to the placebo 
group.
It was studied the microscopic appearance of the prostate 
in healthy rats, those given placebo, and those administered 
Adenoprosin or Vitaprost.
Thus, in healthy rats the parenchyma of the prostate was 
represented by the terminal sections of the tubular alveolar 
glands. Most glands had a broad lumen with a large amount 
of secretion, which helps the plies of the epithelial mucosa 
to be smooth and the epithelial cells get a cubic form. Thin 
layers of muscle-elastic tissue were located between the se-
cretory units of the gland.
In animals subjected to surgical ligation of the anterior 
prostate lobe receiving placebo, the histological examination 
showed the presence of an acute prostatitis: pronounced in-
terstitial edema with evident vascular congestion. The secre-
tory epithelium was atrophied and absent glandular secre-
tion.
In rats receiving Adenoprosin 150 mg rectal supposito-
ries, the microscopic image of the prostate showed a decrease 
in the severity of the inflammatory process. The parenchyma 
of the prostate had a normal structure, the terminal sections 
being covered with a columnar secretory epithelium. At the 
same time, there were also sectors with stromal edema, but 
much less pronounced than in the control group without 
signs of vascular congestion. A similar morphological im-
age of the prostate was observed in the animals treated with 
Vitaprost, 50 mg rectal suppositories (fig.1).
From a quantitative point of view, the anti-inflammatory 
action of the studied products was assessed by determining 
the surface area of epithelial cells on the gland section, the 
number and the surface of the blood vessels and the number 
of acini with desquamated epithelium per 100 consecutive 
marginal sections (tab. 5).
Thus, compared to intact (healthy) rats in placebo-treat-
ed animals, a significant numerical reduction of the surface 
of epithelial cells and blood vessels is observed, with an in-
creased level of epithelial desquamation. In animals treated 
with Adenoprosin, 150 mg rectal suppositories, or with Vi-
taprost, 50 mg rectal suppositories, these numbers are much 
closer to those of the control group.
The action of the product Adenoprosin, 150 mg rectal 
suppositories, or Vitaprost, 50 mg rectal suppositories  
on the model of chronic prostatitis
Chronic bacterial prostatitis was modelled by intra-op-
erative ligation of the right prostate lobe. The treatment was 
initiated 30 days after the ligation and had duration of 15 
days. Under assessment was the action of the products on 
rat body mass and anti-inflammatory action confirmed by 
morphological changes of the prostate.
Body mass was determined every 7 days from the mod-
elled chronic non-bacterial prostatitis and until the end of 
treatment. In intact animals a constant increase in body 
mass throughout the observation period was determined. 
Table 4
Modification of the prostate weight index under the influence of the administered products
Assessed period 
Group 1
Healthy
Group 2
Placebo
Adenoprosin® Vitaprost®
T Dose T x 3 Dose T Dose T x 3 Dose
 7 days of inflammation 2,09±0,03  1,71±0,05*  1,99±0,12# 2,12±0,10#   1,97±0,08#   2,00±0,05#
*- statistically veridical difference compared to group 1 (healthy, intact rats (р<0,05, Mann-Whitney  criteria, #  -  veridical difference compared to 
control group, placebo (р<0,05).
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In animals with chronic prostatitis, a progressive decrease 
in body mass was observed immediately after the interven-
tion. This decrease continued in rats placebo-treated. In rats 
receiving the Adenoprosin or Vitaprost products, weight loss 
stopped immediately after initiation of therapy and after 15 
days of treatment weight gain was recorded (tab. 6).
After the evaluation of the animals included in the study, 
was noticed that the use of Adenoprosin, 150 mg rectal sup-
positories, and Vitaprost 50 mg rectal suppositories, contri-
buted to the increase in body mass index in rats with non-
bacterial chronic prostatitis, compared to placebo-treated 
rats. Differences between the actions of the products were 
not noticed.
The morphological examination started with the deter-
mination of prostate weight at 45 days after the modelling of 
chronic prostatitis (tab. 7).
Histological examination at 45 days after modelled 
chronic non-bacterial prostatitis in placebo-treated rats 
showed the presence of interstitial edema, vascular con-
gestion with connective tissue proliferation, high fibroblast 
content and inflammatory lymphocytic infiltration. The se-
cretory epithelium was atrophied, and secretion at terminal 
Table 5
The action of Adenoprosin, 150 mg rectal suppositories, or Vitaprost, 50 mg rectal suppositories,  
upon the prostate structure through the treatment of acute aseptic prostatitis (group n = 10)
Parametres
Group 1
healthy
Group 2
Placebo
Adenoprosin® Vitaprost®
T Dose Tx 3 Dose T Dose T x 3 Dose
The surface of the epithelial cells 20,8±1,2  8,3±0,9*  12,4±1,3*  16±1,2#  13±1,3*  17±0,9# 
The surface of the blood vessels 0,3±0,04  1,2±0,2*  0,7±0,08  0,5±0,05  0,6±0,2  0,5±0,04 
The number of the acini with 
desquamated epithelium per 
100 sections
3,2±0,09  15±1,2*  11,3±0,9*  9,4±0,7*#  11,2±0,8*  8,5±0,6*# 
* - veridical difference compared to group 1, healthy, intact rats (р<0,05), Mann-Whitney  criteria, #  –  veridical difference compared to control group, 
placebo (р<0,05).
Table 6
The action of Adenoprosin, 150 mg rectal suppositories, or Vitaprost, 50 mg rectal suppositories upon the rat’s body 
mass index under the treatment of chronic non-bacterial prostatitis (group n =10)
Parametres
Group 1
healthy
Group 2
Placebo
Adenoprosin® Vitaprost®
T Dose T x 3 Dose T Dose T x 3 Dose
Incipient 299,50±2,24  300,00 ±2,26 297,90 ± 1,57 300,30 ±1,88 296,80 ±2,00 299,70 ±2,44
7 days after 314,60 ±0,85 280,00 ±1,91* 278,60 ±1,87* 277,40 ±1,77* 282,10 ±1,96* 283,90 ±2,02*
14 days after 323,50±1,11 265,20±1,25* 265,70±0,88* 264,20±1,05* 264,00±1,24* 263,00±0,92*
21 days after 333,40±0,86 243,70±0,93* 244,00±1,04* 244,90±1,00* 244,50±1,09* 244,60±1,09*
30 days after 338,20±0,85 237,70 ±1,05* 239,10 ±1,00* 237,60 ±1,42* 237,20 ±1,00* 234,00 ±0,58*
15 days on treatment or 
placebo
361,60±1,16# 223,80±0,98* 259,30±1,17*# 260,10±0,99*# 260,60±0,88*# 261,60±0,86*#
* - veridical difference compared to group 1, healthy, intact rats (р<0,05), Mann-Whitney  criteria, #  –  veridical difference compared to control group, 
placebo (р<0,05).
Table 7
The action of Adenoprosin, 150 mg rectal suppositories, or Vitaprost, 50 mg rectal suppositories upon the rats prostate 
weight under the treatment of chronic non-bacterial prostatitis (group n =10)
Assessed period Group 1
healthy
Group 2
Placebo
Adenoprosin® Vitaprost®
T Dose T x 3 Dose T Dose T x 3 Dose
 45 days after modelling/ 15 days after 
treatment
2,04±0,03 1,78±0,05* 2,02±0,04# 2,00±0,03# 2,02±0,08# 2,05±0,07#
* - veridical difference compared to group 1, healthy, intact rats (р<0,05), Mann-Whitney  criteria, #  – veridical difference compared to control group, 
placebo (р<0,05).
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level absent. The presence of segments with epithelial des-
quamation and obvious dilatation of terminal sections due 
to exudative fluid accumulation was reported.
In rats treated with Adenoprosin, a reduction in intersti-
tial edema and vascular congestion in the prostate was ob-
served. The macroscopic aspect of the prostatic parenchyma 
was close to the usual one, secretory columnar cells and ac-
tive secretion were present in the epithelium of the terminal 
sections.
Only a few portions have been noted with residual signs 
of chronic inflammation in the form of stromal lymphocytic 
infiltrate. The microscopic picture of the prostate of the rats 
treated with Vitaprost was similar (fig.2).
The anti-inflammatory effect of Adenoprosin product, 
150 mg rectal suppositories, was also expressed by increa-
Table 8
The action of Adenoprosin, 150 mg rectal suppositories, or Vitaprost, 50 mg rectal suppositories, upon the prostate 
structure through the treatment of chronic nonbacterial prostatitis (group n = 10)
Parametres Group 1
healthy
Group 2
Placebo
Adenoprosin® Vitaprost®
T Dose T x 3 Dose T Dose T x 3 Dose
The surface of the epithelial cells 20,5±1,4  7,4±0,9*  12,3±1,2*  17,6±1,6#  11,8*±0,9  18,9±1,2# 
The surface of the blood vessels 0,3±0,03  1,1±0,2*  0,6±0,2#  0,5±0,1#  0,5±0,09#  0,5±0,04# 
The number of the acini with 
desquamated epithelium per 100 
sections 
3,3±0,7  50,5±1,4*  35,2±1,6*#  20,4±1,2*# 34,1±1,5*#  25,2±1,6*#
The surface of the collagen fibres 1,5±0,4  15,4±0,5*  13,6±0,7*  10,2±0,9*#  14,3±0,2*  11,1±0,5*# 
* - veridical difference compared to group 1, healthy, intact rats (р<0,05), Mann-Whitney  criteria, #  -  veridical difference compared to control group, 
placebo (р<0,05).
Fig. 2.  Microscopic prostate structure: a) intact prostate,  
b) nonbacterial chronic prostatitis treated with placebo,  
c) non-bacterial chronic prostatitis treated with Adenoprosin, 
rectal suppositories 38 mg/kg, d) non-bacterial chronic 
prostatitis treated with Vitaprost, rectal suppositories 12 mg/kg. 
Hematoxylin-eosin, x 100.
Fig. 1.  Microscopic prostate structure: a) intact prostate,  
b) acute prostatitis treated with placebo, c) acute prostatitis 
treated with Adenoprosin, rectal suppositories 38 mg/kg,  
d) Vitaprost treated prostatitis, rectal suppositories 12 mg/kg. 
Hematoxylin-eosin, x 100.
sing the surface of the epithelial cells in the terminal sec-
tions, reducing the surface of vascular congestion and the 
number of acini with desquamated epithelium. There were 
no signs of an increase in the number of collagen fibers in 
prostate tissue (tab. 8).
In this way it has been shown that the product Adeno-
prosin, 150 mg rectal suppositories significantly reduce signs 
of inflammation in rats with modelled chronic nonbacterial 
prostatitis.
Discussion
The problem of chronic prostatitis is not fully elucidated. 
According to national and international clinical protocols 
the treatment of chronic prostatitis is complex with the use 
of antimicrobial, antiinflammatory, antioxidant, α-receptor 
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blockers, phytotherapeutic products, etc. The duration of 
treatment would be at least 28 days. At the same time, the 
long-term administration of some pharmacological drugs 
may cause a number of adverse effects, including: hypoten-
sion or retrograde ejaculation due to the use of α-blockers; 
libido disappearance or erectile dysfunction due to use of 
5α-reductase inhibitors; peptic ulcers, dyspepsia, increased 
risk of cardiovascular events from using non-steroidal anti-
inflammatory drugs, etc [19, 20, 21, 22].
Therefore, researches into the development of new phar-
maceutical products for the treatment of chronic prostatitis 
continues. Evaluation of products on experimental models 
of prostatitis is one of the most viable solutions to appreciate 
their action. Most products used to treat chronic bacterial 
prostatitis were originally tested on animal models.
The product Cernitin, containing pollen extract, used in 
the treatment of chronic prostatitis has been tested on non-
bacterial-induced prostatitis models in rats. Induction of 
non-bacterial prostatitis was modelled by administration of 
estradiol after castration. Histopathological evaluation of the 
prostate during the post-treatment period determined ame-
lioration of the epithelial score, respectively the reduction of 
the glandular atrophy, along with the inhibition of stromal 
proliferation [23].
Another herbal product (WSY-1075), tested on non-
bacterial prostatitis models induced in Wistar rats, showed 
that the product significantly reduced the level of prostate 
proinflammatory cytokines (IL-6 and IL-8) and histological 
lesions after 8 weeks of administration compared to the con-
trol group [24].
A Finnish study has shown that the spruce extract, orally 
administered for 18 weeks to rats with non-bacterial prosta-
titis induced experimentally relieves pain and urine evacua-
tion without adverse effects [25].
Several studies recommend the use of products with or-
ganotropic action on the prostate for the improvement of lo-
cal haemodynamic indices [26, 27, 28].
Prostatilen, a product similar to the product included in 
our study, Vitaprost, contains regulating peptides extracted 
from the bovine prostate, was tested in rat models weighing 
180-200g, to which prostatitis was induced by injection of 
10% dimexide solution. The experiment demonstrated the 
organotropic anti-inflammatory effect of the product [29].
The use of bovine prostate peptides (cytomedins) has 
been known for many years. They are recommended for 
their local anti-inflammatory effect and immunomodula-
tory properties. In several clinical trials, their effect on the 
evolution of chronic prostatitis and benign prostatic hyper-
plasia was noted [30, 31].
Adenoprosin is a product that contains lipoproteins that 
have organotropic action on the prostate. These lipoproteins 
are obtained from Lymantria dispar larvae by a major new 
method. Biologically active components of the product con-
tribute to the reduction of A2 phospholipase formation and 
arachidonic acid elimination, followed by a decrease in pros-
taglandin and leukotriene production [32].
The study assessed the effect of Adenoprosin on the ex-
perimental model of non-bacterial acute and chronic prosta-
titis administered as rectal suppositories. After the morpho-
logical examination of the aseptic acute prostatitis model, a 
decrease in the severity of the inflammatory process, mani-
fested by decreased stromal edema and vascular congestion, 
was observed. After the quantitative evaluation of Adeno-
prosin action compared to the control group treated with 
placebo and the reference product Vitaprost, in animals 
without organotropic treatment it was observed a signifi-
cantly reduced surface of epithelial cells, reduced number 
of blood vessels, and increased level of epithelial desquama-
tion. In rats with aseptic acute prostatitis treated with Ad-
enoprosin or Vitaprost, these indices were much closer to 
the control group and healthy rats.
On the experimental model of non-bacterial chronic 
prostatitis, both the tested and the reference products acted 
by reducing interstitial edema and vascular congestion. The 
histological appearance of the prostate is suggestive. In rats 
with non-bacterial chronic prostatitis without treatment, the 
secretory epithelium is clearly atrophied, interstitial edema 
and vascular congestion are reported. Under the action of 
organotropic products, there is a significant reduction in 
edema, and residual signs of inflammation are present only 
in certain sectors.
The results of our study are encouraging and open new 
perspectives for the treatment of non-bacterial chronic pros-
tatitis.
Conclusions
The product of entomological origin Adenoprosin 150 
mg rectal suppositories tested in the experimental study of 
aseptic acute prostatitis showed an obvious anti-inflamma-
tory effect.
The anti-inflammatory activity of the product Adenopro-
sin is also manifested in the non-bacterial chronic prostati-
tis model by restoring morphological status of the secretory 
epithelium, reducing interstitial edema, vascular congestion 
and the number of acini with prostate desquamation.
The anti-inflammatory activity of Adenoprosin 150 mg 
rectal suppository on the experimental model of aseptic or 
chronic non-bacterial prostatitis induced on Wistar white 
rats is similar to that of the reference product Vitaprost, 50 
mg rectal suppositories and is significant compared to pla-
cebo.
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